Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland.

Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland.

Publication date: Jun 14, 2024

Several population-level studies have described individual clinical risk factors associated with suboptimal antibody responses following COVID-19 vaccination, but none have examined multimorbidity. Others have shown that suboptimal post-vaccination responses offer reduced protection to subsequent SARS-CoV-2 infection; however, the level of protection from COVID-19 hospitalisation/death remains unconfirmed. We use national Scottish datasets to investigate the association between multimorbidity and testing antibody-negative, examining the correlation between antibody levels and subsequent COVID-19 hospitalisation/death among double-vaccinated individuals. We found that individuals with multimorbidity ( ≥ five conditions) were more likely to test antibody-negative post-vaccination and 13. 37 [6. 05-29. 53] times more likely to be hospitalised/die from COVID-19 than individuals without conditions. We also show a dose-dependent association between post-vaccination antibody levels and COVID-19 hospitalisation or death, with those with undetectable antibody levels at a significantly higher risk (HR 9. 21 [95% CI 4. 63-18. 29]) of these serious outcomes compared to those with high antibody levels.

Open Access PDF

Concepts Keywords
Covid Antibody
Death Conditions
High Covid
Scotland Death
Vaccinated Hospitalisation
Individuals
Multimorbidity
Negative
Outcomes
Post
Protection
Risk
Suboptimal
Subsequent
Vaccination

Semantics

Type Source Name
disease VO vaccination
disease MESH COVID-19
disease VO population
pathway REACTOME SARS-CoV-2 Infection
disease MESH death
disease VO vaccinated
disease VO dose
disease VO vaccine
disease VO effectiveness
disease MESH infection
disease MESH lifestyle factors
disease IDO blood
disease MESH cancer
disease MESH hypertension
disease IDO immunodeficiency
disease MESH stroke
disease MESH sequelae
disease VO time
disease MESH asthma
pathway KEGG Asthma
disease MESH mental illnesses
drug DRUGBANK Coenzyme M
disease MESH coronary heart disease
disease MESH cirrhosis
disease MESH obesity
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease VO vaccine dose
disease MESH multiple sclerosis
disease MESH chorea
disease MESH pulmonary hypertension
disease IDO history
disease MESH heart failure
drug DRUGBANK Trestolone
disease IDO immunosuppression
disease MESH chronic kidney disease
disease IDO immune response

Original Article

(Visited 1 times, 1 visits today)